BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 13, 2005
View Archived Issues
Myogen Riding High After Preliminary PAH Findings
Positive Phase III news sent Myogen Inc.'s stock soaring 40.5 percent, with top-line data demonstrating ambrisentan's ability to improve symptoms of pulmonary arterial hypertension. (BioWorld Today)
Read More
Pain Therapeutics Quitting IBS Drug On Phase III Miss
Read More
Gemin X's GX15-070: 'Hints Of Efficacy' In Phase I Work
Read More
GlycoFi's Largest-Ever Alliance: Potential $100M Via Merck Deal
Read More
Other News To Note
Read More